Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: A review of its clinical pharmacology, efficacy and safety

Expert Review of Clinical Immunology

Volumn 10, Issue 10, 2014, Pages 1281-1291

  Jones, David E ^a   Goldman, Myla D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

alemtuzumab; monoclonal antibody; multiple sclerosis

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BETA1A INTERFERON; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 12; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; NEUROTROPHIC FACTOR; PARACETAMOL; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BETA INTERFERON; TERIFLUNOMIDE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

AUTOIMMUNE DISEASE; AUTOIMMUNE HYPOTHYROIDISM; AUTOIMMUNE THYROIDITIS; CONTRAST ENHANCEMENT; DISABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FEVER; FLU LIKE SYNDROME; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRAVES DISEASE; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATION; INFUSION RELATED REACTION; INJECTION SITE REACTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROTEIN SECRETION; RASH; RECURRENT DISEASE; RELAPSE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84907260470     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.951332     Document Type: Review

References (75)

1. National Multiple Sclerosis Society. Multiple Sclerosis: Just the. facts. 2011
2. Noseworthy JH, Lucchinetti C, Rodriquez M, et al. Multiple Sclerosis. N Engl J Med 2000;343:938-52
3. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012;112:1180-8
4. Compston A. Coles, A. Multiple Sclerosis. Lancet 2008;372:1502-17
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33: 1444-52
6. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871-2
7. Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003;61:1367-73
8. Ontaneda D, LaRocca N, Coetzee T, et al. Revisiting the multiple sclerosis functional composite: Proceedings from the National Multiple Sclerosis Society (NMSS) task force on clinical disability measures. Mult Scler 2012;18:1074-80
9. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiographic disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapse-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8: 254-60
10. Bevan CJ, Cree BAC. Disease Activity Free Status: A new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 2014;71:269-70
11. Schwid SR, Panitch HS. Full results of the Evidence of interferon dose-response European North American comparative efficacy (Evidence) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007;29: 2031-48
12. O'Connor P, Filiippi M, Arnason B, et al. 250 mg or 500 mg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomized, multicentre study. Lancet Neurol 2009;8:889-97
13. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs glatiramer acetate in relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
14. Fox RJ, Miller DH, Phillips T, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
15. Vermersch P, Czlonkowska A, Grimaldi LME, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomized, controlled phase 3 trial. Mult Scler 2014;20:705-16
16. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
17. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56
18. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
19. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56
20. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
21. Confavreux C, O'Connor P. Comi Giancarlo, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56
22. Voller TL, Sorensen PS, Salmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 2014;261:773-83
23. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9
24. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: Treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011;17:970-9
25. Xia MQ, Hale G, Lifely MR, et al. Structure of the Campath-1 antigen: A glycosylphosphatidylinositol-Anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-40
26. Xia MQ, Tone M, Packman L, et al. Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991;21: 1677-84
27. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies-A focus on alemtuzumab. Clin Immunol 2012;142:25-30
28. +regulatory T cells. Clin Immunol 2006;120:247-59
29. Hu Y, Turner MJ, Shields J. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128:260-70
30. Turner MJ, LaMorte MJ, Chretien N. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol 2013;261:29-36
31. European Medicines Agency Product Information. Available from: Http://www. ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/003718/ WC500150521.pdf
32. Hill-Cawthorne GA, Button B, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:298-304
33. Cox AL, Thompson SAJ, Jones JL, et al. Lymphocyte homeostatis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35: 3332-42
34. Thompson SAJ, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010;30: 99-105
35. Graves J, Galetta SL, Palmer J, et al. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. Mult Scler 2013;19:1302-9
36. Button T, Altmann D, Tozer D, et al. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult Scler 2013;19:241-4
37. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD11a/ CD18 (LFA-1) on NK cells. J Clin Invest 1996;98:2819-26
38. Moreau T, Coles AJ, Wing M, et al. Transient increase in symptoms associated with a cytokine release in patients with multiple sclerosis. Brain 1996;119:225-37
39. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304
40. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108
41. ClinicalTrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00050778
42. CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359: 1786-801
43. Coles A, Fox E. Vladic A, et a. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinic trial. Neurology 2012;78:1069-78
44. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10: 338-248
45. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment with multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010;133:2232-47
46. Fox EJ, Sullivan HC, Gazda SK, et al. A single-Arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012;19:307-11
47. Hirst CL, Pace A, Pickersgill TP, et al. CAMPATH 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-8
48. ClinicalTrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00530348
49. ClinicalTrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00548405
50. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012;380:1819-28
51. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease modifying therapy: A randomised controlled phase 3 trial. Lancet 2012;380:1829-39
52. ClinicalTrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00930553
53. Fox EJ, Arnold DL, Cohen JA, et al. Durable efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who participated in the CARE-MS studies: Three year follow-up. Poster presented at the American Academy of Neurology; 16-23 March 2013; San Diego, CA, USA
54. Arnold DL, Cohen JA, Barkof F, et al. Alemtuzumab improves brain MRI outcomes in patients with active relapsing-remitting multiple sclerosis: Three-year follow-up of the Care-MS studies. Poster presented at the American Academy of Neurology; 26 April-3 May 2014; Philadelphia, PA, USA
55. Meyer D, Coles A, Oyuela P, et al. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult Scler Rel Dis 2013;2:60-3
56. Clatworthy MR, Wallin EF, Jayne DR Jr. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008;359:768-9
57. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 2011;118:6299-305
58. Twyman CL, Oyuela P, Palmer J, et al. Thyroid autoimmune adverse events in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis: Four-year follow-up of the CARE-MS studies. Poster presented at the American Academy of Neurology, 26 April-3 May 2014; Philadelphia, PA, USA
59. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77: 573-9
60. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-61
61. Jones JL, Thompson SAJ, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatis T-cell proliferation. PNAS 2013;110:20200-5
62. McCarthy CL, Tuohy O, Compston AS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 2013;81:872-6
63. Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013;80:55-61
64. Kousin-Ezewu O, Azzopardi L, Parker RA, et al. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 2014;82:1-7
65. Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur J Neurol 2009;16:e70-1
66. Cohen J, Reingold S, Polman C, et al. International advisory committee on clinical trials in multiple sclerosis. Disability outcome measures in multiple sclerosis clinical trials: Current status and future prospects. Lancet Neurol 2012;11:467-76
67. Polman CH, OConnor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
68. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-Associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
69. Marriott JJ, Miyasaki JM, Bronseth G, et al. Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-70
70. Edwards K, LaGanke C, Oyuela P, et al. Safety of using disease-modifying therapy post-Alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis in the core and extensions phases of CAMMS223, CARE-MS 1, and CARE-MS II studies. Poster presented at the American Academy of Neurology, 26 April-3 May 2014; Philadelphia, PA, USA
71. Hauser SL, Waubant E, Arnold DA, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
72. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomized, placebo-controlled, multicenter trial. Lancet 2011;378:1779-87
73. Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study. Neurology 2014;82:573-81
74. Gold R, Giovannoni G, Selmay K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomized, double-blind, placebo-controlled trial. Lancet 2013; 381(9884):2167-75
75. Cadavid D, Phillips G, Dong-Si T, et al Efficacy and safety of anti-LINGO-1 for the treatment of relapsing forms of multiple sclerosis: Design of the Phase 2 SYNERGY trial. Poster presented at the American Academy of Neurology, 26 April-3 May 2014; Philadelphia, PA, USA\